{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:52:25Z","timestamp":1773251545076,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"vor","delay-in-days":137,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.5604\/01.3001.0012.7909","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T06:12:02Z","timestamp":1544767922000},"page":"172-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Experience with Sorafenib in 3 Hospitals in Sao Paulo"],"prefix":"10.1016","volume":"18","author":[{"given":"Rog\u00e9rio","family":"Camargo-Pinheiro-Alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele E.","family":"Viera-Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Malzyner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otavio","family":"Gampel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaisa de F.","family":"Almeida-Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty","family":"Guz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.5604\/01.3001.0012.7909_bib0010","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update.","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0012.7909_bib0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.5604\/01.3001.0012.7909_bib0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.5604\/01.3001.0012.7909_bib0025","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ijcp.12352","article-title":"GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.","volume":"68","author":"Lencioni","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.5604\/01.3001.0012.7909_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cld.530","article-title":"Limitations of the Barcelona Clinic Liver Cancer Staging System With a Focus on Transarterial Chemoembolization as a Key Modality for Treatment of Hepatocellular Carcinoma.","volume":"7","author":"Barman","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.5604\/01.3001.0012.7909_bib0035","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","article-title":"Population-based risk factors and resource utilization for HCC: US perspective.","volume":"26","author":"Sanyal","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.5604\/01.3001.0012.7909_bib0040","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/bjc.2013.410","article-title":"Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.","volume":"109","author":"Palmer","year":"2013","journal-title":"Br J Cancer"},{"key":"10.5604\/01.3001.0012.7909_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cgh.2012.10.040","article-title":"Multidisciplinary management of patients with cirrhosis: a need for care coordination.","volume":"11","author":"Mellinger","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.5604\/01.3001.0012.7909_bib0050","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.5604\/01.3001.0012.7909_bib0055","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0012.7909_bib0060","doi-asserted-by":"crossref","first-page":"s115","DOI":"10.1002\/lt.20034","article-title":"The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.","volume":"10","author":"Llovet","year":"2004","journal-title":"Liver Transpl"},{"key":"10.5604\/01.3001.0012.7909_bib0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.5604\/01.3001.0012.7909_bib0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.5604\/01.3001.0012.7909_bib0075","doi-asserted-by":"crossref","first-page":"56147","DOI":"10.18632\/oncotarget.11269","article-title":"OASIS 2: online application for survival analysis 2 with features for the analysis of maximal lifespan and healthspan in aging research.","volume":"7","author":"Han","year":"2016","journal-title":"Oncotarget"},{"key":"10.5604\/01.3001.0012.7909_bib0080","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2014.03.030","article-title":"Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.","volume":"61","author":"Reig","year":"2014","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0012.7909_bib0085","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1002\/cncr.27543","article-title":"The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.","volume":"118","author":"Chiu","year":"2012","journal-title":"Cancer"},{"key":"10.5604\/01.3001.0012.7909_bib0090","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/00365521.2012.683040","article-title":"Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.","volume":"47","author":"Woo","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.5604\/01.3001.0012.7909_bib0095","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.7314\/APJCP.2013.14.12.7367","article-title":"Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.","volume":"14","author":"Berk","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.5604\/01.3001.0012.7909_bib0100","doi-asserted-by":"crossref","first-page":"931972","DOI":"10.1155\/2013\/931972","article-title":"Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.","volume":"2013","author":"Kostner","year":"2013","journal-title":"Sci World J"},{"key":"10.5604\/01.3001.0012.7909_bib0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12094-012-0902-3","article-title":"Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.","volume":"15","author":"Zugazagoitia","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"10.5604\/01.3001.0012.7909_bib0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jnci.2013.08.003","article-title":"Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.","volume":"26","author":"Abdel-Rahman","year":"2014","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.5604\/01.3001.0012.7909_bib0115","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s12032-014-0948-x","article-title":"Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.","volume":"3","author":"Imedio","year":"2014","journal-title":"Med Oncol"},{"key":"10.5604\/01.3001.0012.7909_bib0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12885-015-1273-2","article-title":"Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.","volume":"15","author":"Lee","year":"2015","journal-title":"BMC Cancer"},{"key":"10.5604\/01.3001.0012.7909_bib0125","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1148\/radiol.2015150667","article-title":"TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.","volume":"279","author":"Geschwind","year":"2016","journal-title":"Radiology"},{"key":"10.5604\/01.3001.0012.7909_bib0130","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:42:13Z","timestamp":1761648133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119303199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1665268119303199"],"URL":"https:\/\/doi.org\/10.5604\/01.3001.0012.7909","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience with Sorafenib in 3 Hospitals in Sao Paulo","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/01.3001.0012.7909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}